Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Wellness Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$5,615,742

747 payments

Through program year 2025, Wellness Clinical Research LLC is reported as receiving $5,615,742 in research payments, across 747 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $572,367 65
2024 Research $1,010,390 124
2023 Research $2,202,606 202
2022 Research $480,181 53
2021 Research $414,997 61
2020 Research $379,387 127
2019 Research $555,814 115

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $2,377,396 98 payments
  2. Sanofi Pasteur Inc. $943,380 42 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $571,899 170 payments
  4. Genentech, Inc. $486,856 96 payments
  5. Pfizer Inc. $395,108 90 payments
  6. Allergan Inc. $355,967 111 payments
  7. AbbVie, Inc. $251,429 52 payments
  8. Roche Products Limited $81,308 50 payments
  9. Galderma Laboratories, L.P. $63,382 18 payments
  10. Teva Pharmaceuticals USA, Inc. $45,586 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older $625,812 20 payments
  2. A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet $492,102 134 payments
  3. Roche Cancer Screening Collection Study $380,656 38 payments
  4. A Phase 3B Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $368,773 2 payments
  5. A Phase 3B, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $346,052 3 payments
  6. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-4) $295,101 4 payments
  7. A Randomized, Double Blind, Placebo Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine the Rebuild 2 Study $248,086 8 payments
  8. A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities (Attain-Maintain) $235,982 2 payments
  9. Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older $213,594 11 payments
  10. Jak1 Dupilumab Comparator Study $204,349 24 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $4,765 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record